Bank of New York Mellon Corp boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 123,832 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,404 shares during the quarter. Bank of New York Mellon Corp owned 0.59% of ANI Pharmaceuticals worth $6,845,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. grew its stake in shares of ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after buying an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after buying an additional 340,854 shares during the last quarter. abrdn plc bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $13,155,000. Bank of Montreal Can bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth $13,043,000. Finally, Mizuho Markets Americas LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth $11,670,000. 76.05% of the stock is owned by institutional investors.
ANI Pharmaceuticals Stock Up 3.6 %
Shares of NASDAQ ANIP traded up $2.25 during trading on Monday, hitting $64.74. 53,693 shares of the company traded hands, compared to its average volume of 237,665. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The business's fifty day moving average is $58.40 and its 200 day moving average is $58.06. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -117.20 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81.
Wall Street Analyst Weigh In
A number of analysts have weighed in on ANIP shares. Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target on the stock. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday. Finally, Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a report on Friday. They set a "buy" rating and a $80.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $79.75.
Check Out Our Latest Stock Report on ANIP
Insider Buying and Selling
In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,700 shares of company stock valued at $610,201. 12.70% of the stock is owned by company insiders.
About ANI Pharmaceuticals
(
Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
